Stock Track | Viatris Plunges 7.21% Pre-Market on Disappointing Q4 Earnings

Stock Track

Feb 27, 2025

Viatris Inc. (VTRS) stock plummeted 7.21% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results.

The pharmaceutical giant reported adjusted earnings per share of $0.54, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking an 8.13% year-over-year decline.

As a global healthcare company focused on providing access to high-quality medicines worldwide, Viatris' ability to meet or exceed earnings expectations is crucial for investor confidence. The missed targets on both earnings and revenue suggest challenges in executing the company's growth strategy, which likely weighed heavily on the stock's performance in early trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1143074068"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143074068\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143074068?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143074068","market":"hk","top_or_hot":-1,"title":"Stock Track | Viatris Plunges 7.21% Pre-Market on Disappointing Q4 Earnings","media":"Stock Track","content":"<p>Viatris Inc. (VTRS) stock plummeted 7.21% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results.</p>\n\n<p>The pharmaceutical giant reported adjusted earnings per share of $0.54, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking an 8.13% year-over-year decline.</p>\n\n<p>As a global healthcare company focused on providing access to high-quality medicines worldwide, Viatris' ability to meet or exceed earnings expectations is crucial for investor confidence. The missed targets on both earnings and revenue suggest challenges in executing the company's growth strategy, which likely weighed heavily on the stock's performance in early trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Viatris Plunges 7.21% Pre-Market on Disappointing Q4 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Viatris Plunges 7.21% Pre-Market on Disappointing Q4 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 19:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viatris Inc. (VTRS) stock plummeted 7.21% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results.</p>\n\n<p>The pharmaceutical giant reported adjusted earnings per share of $0.54, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking an 8.13% year-over-year decline.</p>\n\n<p>As a global healthcare company focused on providing access to high-quality medicines worldwide, Viatris' ability to meet or exceed earnings expectations is crucial for investor confidence. The missed targets on both earnings and revenue suggest challenges in executing the company's growth strategy, which likely weighed heavily on the stock's performance in early trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTRS","symbol_name":"Viatris Inc.","start_time":0,"source_url":"","article_id":"1143074068","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143074068","pubTimestamp":1740657413,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Viatris Inc.  stock plummeted 7.21% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results.The pharmaceutical giant reported adjusted earnings per share of $0.54, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking an 8.13% year-over-year decline.As a global healthcare company focused on providing access to high-quality","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTRS":"Viatris Inc."},"translate_title":"股票跟踪Viatris因第四季度盈利令人失望而盘前暴跌7.21%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":1},"content_text":"Viatris Inc. (VTRS) stock plummeted 7.21% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results.\nThe pharmaceutical giant reported adjusted earnings per share of $0.54, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking an 8.13% year-over-year decline.\nAs a global healthcare company focused on providing access to high-quality medicines worldwide, Viatris' ability to meet or exceed earnings expectations is crucial for investor confidence. The missed targets on both earnings and revenue suggest challenges in executing the company's growth strategy, which likely weighed heavily on the stock's performance in early trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}